Fig. 4From: 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatmentEORTC Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)Back to article page